Pharmaceutical company · GSK

GSK
clinical trial
pipeline

Registry checked

Published

Belantamab mafodotin is linked to 19 distinct active studies, with 3 Phase 1, 9 Phase 2, 7 Phase 3. Depemokimab is linked to 9 distinct active studies, with 8 Phase 3, 1 Phase 4.

Phase 2 study NCT05723562 in Neoplasms, Rectal lists estimated primary completion on 2 November 2026. Phase 2 study NCT05565378 in Lung Cancer, Non-Small Cell lists estimated primary completion on 9 November 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

202active trials
as lead sponsor
  • Phase 149
  • Phase 262
  • Phase 378
  • Phase 49
  • Phase not recorded4

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

4126 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later by 108 days

2029-09-24 (estimated)2030-01-10 (estimated)
24 Sept 202910 Jan 2030

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

NCT07607925 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020200022
2026-10-031010242
2026-10-040000000
2026-10-051400164
2026-10-061000011
2026-10-070000221
2026-10-080000000
2026-10-090000000
2026-10-101000232
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-141010021
2026-10-152220064
2026-10-161000011
2026-10-170000000
2026-10-180000000
2026-10-190110131
2026-10-201100022
2026-10-210000111
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000111
2026-10-280000221
2026-10-291110031
2026-10-301100021
2026-10-310000000
Type totals111260124126 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Belantamab mafodotin

Blenrep

19
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 29
  • Phase 37
  • Phase 40
  • Phase not recorded0
Studied condition
Amyloidosis · Multiple Myeloma · Newly Diagnosed Multiple Myeloma
Next primary completion
Not reported
Open drug

Dostarlimab

jemperli

16
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 27
  • Phase 36
  • Phase 42
  • Phase not recorded0
Studied condition
Carcinoma · Colonic Neoplasms · Endometrial Carcinoma
Next primary completion
02 November 2026 · estimated
Open drug

Depemokimab

exdensur

9
Active trials
7
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 38
  • Phase 41
  • Phase not recorded0
Studied condition
Asthma · Eosinophilic Granulomatosis With Polyangiitis · Hypereosinophilic Syndrome
Next primary completion
01 March 2027 · estimated
Open drug

GSK5784283

Canonical investigational asset

8
Active trials
7
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Asthma · Nasal Polyps · Pulmonary Disease, Chronic Obstructive
Next primary completion
Not reported
Open drug

Velzatinib

Canonical investigational asset

7
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 22
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Gastrointestinal Neoplasms · Gastrointestinal Stromal Neoplasms · Healthy Participants
Next primary completion
Not reported
Open drug

Efimosfermin Alfa

Canonical investigational asset

6
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Liver Diseases, Alcoholic · Metabolic Dysfunction-associated Steatohepatitis · Non-alcoholic Fatty Liver Disease
Next primary completion
Not reported
Open drug

183 of 202 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 183 of 202 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

GSK trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
AZUR-1
Dostarlimab

NCT05723562

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 03 Apr 2023 · actual
    Primary completion: 02 Nov 2026 · estimated
    Study completion: 11 Oct 2029 · estimated

    2021202220232024202520262027202820292030
    A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
    Dostarlimab

    NCT05565378

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

    5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    5 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 14 Oct 2022 · actual
      Primary completion: 09 Nov 2026 · estimated
      Study completion: 06 Dec 2027 · estimated

      2021202220232024202520262027202820292030
      A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
      Investigational varicella vaccine

      NCT06693895

      Phase 3 · Recruiting

      Trial source and qualifications

      A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 26 Nov 2024 · actual
        Primary completion: 23 Nov 2026 · estimated
        Study completion: 23 Nov 2026 · estimated

        2021202220232024202520262027202820292030
        A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women
        dTpa

        NCT07596199

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

        • enrollment change · Recorded 2026-09-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • status flip · Recorded 2026-09-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 29 Jun 2026 · actual
        Primary completion: 23 Nov 2026 · estimated
        Study completion: 31 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        AZUR-4
        Dostarlimab

        NCT06567782

        Phase 2 · Recruiting

        Trial source and qualifications

        A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

        3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        3 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 18 Feb 2025 · actual
          Primary completion: 23 Nov 2026 · estimated
          Study completion: 26 Oct 2028 · estimated

          2021202220232024202520262027202820292030
          RUBY
          Dostarlimab

          NCT03981796

          Phase 3 · Active, not recruiting

          Trial source and qualifications

          A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

          Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          Start clipped at the display horizon.

          1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 18 Jul 2019 · actual
            Primary completion: 26 Nov 2026 · estimated
            Study completion: 26 Nov 2026 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 90 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 32 actual primary completions, 0 untyped primary completions, 10 past estimates, 8 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            77

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology77 trials
            • Infectious Disease58 trials
            • Respiratory27 trials
            • Gastroenterology & Hepatology8 trials
            • Immunology & Inflammation7 trials
            • ENT & Hearing3 trials
            • Metabolic/Endocrine/Nutrition3 trials
            • Cardiovascular2 trials
            • Renal & Urology2 trials
            • Dermatology1 trials
            • Haematology1 trials
            • Neurology1 trials
            • Unmapped12 trials
            • Healthy volunteers0 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            N

            Novartis

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 4,161 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: GSK. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            4,161 distinct registry candidates produced 4,161 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            3,735 scoped records have indexed enrichment and 426 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T00:30:33.710Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 7c670d8ba74f8802ef5c0be86c98a4ec4e471955ca000b330cab2025b12af101.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 4,161 mapped lead-sponsored clinical studies across all statuses. 3,735 have indexed enrichment, 426 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.